These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1027 related articles for article (PubMed ID: 29227302)

  • 1. The target invites a foe: antibody-drug conjugates in gynecologic oncology.
    Campos MP; Konecny GE
    Curr Opin Obstet Gynecol; 2018 Feb; 30(1):44-50. PubMed ID: 29227302
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibody-drug conjugates in gynecologic malignancies.
    Lee EK; Liu JF
    Gynecol Oncol; 2019 Jun; 153(3):694-702. PubMed ID: 30929824
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investigational Antibody-Drug Conjugates for Treatment of B-lineage Malignancies.
    Herrera AF; Molina A
    Clin Lymphoma Myeloma Leuk; 2018 Jul; 18(7):452-468.e4. PubMed ID: 29804872
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Latest Research and Development into the Antibody-Drug Conjugate, [fam-] Trastuzumab Deruxtecan (DS-8201a), for HER2 Cancer Therapy.
    Nakada T; Sugihara K; Jikoh T; Abe Y; Agatsuma T
    Chem Pharm Bull (Tokyo); 2019; 67(3):173-185. PubMed ID: 30827997
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progress in Gynecologic Cancers with Antibody Drug Conjugates.
    O'Malley DM; Calo CA
    Curr Oncol Rep; 2021 Jun; 23(8):89. PubMed ID: 34125311
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody-drug conjugates: an emerging modality for the treatment of cancer.
    Leal M; Sapra P; Hurvitz SA; Senter P; Wahl A; Schutten M; Shah DK; Haddish-Berhane N; Kabbarah O
    Ann N Y Acad Sci; 2014 Aug; 1321():41-54. PubMed ID: 25123209
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel antibody-drug conjugates: current and future roles in gynecologic oncology.
    Tymon-Rosario J; Zeybek B; Santin AD
    Curr Opin Obstet Gynecol; 2021 Feb; 33(1):26-33. PubMed ID: 32618744
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in antibody-drug conjugates for gynecologic malignancies.
    Tymon-Rosario J; Gorman M; Richardson DL; Washington C; Santin AD
    Curr Opin Obstet Gynecol; 2023 Feb; 35(1):6-14. PubMed ID: 36484278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical toxicity of antibody drug conjugates: a meta-analysis of payloads.
    Masters JC; Nickens DJ; Xuan D; Shazer RL; Amantea M
    Invest New Drugs; 2018 Feb; 36(1):121-135. PubMed ID: 29027591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The next generation of antibody drug conjugates.
    Mack F; Ritchie M; Sapra P
    Semin Oncol; 2014 Oct; 41(5):637-52. PubMed ID: 25440608
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibody-drug conjugates for the treatment of lymphoma: clinical advances and latest progress.
    Chu Y; Zhou X; Wang X
    J Hematol Oncol; 2021 Jun; 14(1):88. PubMed ID: 34090506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrating antibody drug conjugates in the management of gynecologic cancers.
    Chelariu-Raicu A; Mahner S; Moore KN; Lorusso D; Coleman RL
    Int J Gynecol Cancer; 2023 Mar; 33(3):420-429. PubMed ID: 36878560
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The evolving landscape of antibody-drug conjugates in gynecologic cancers.
    Tolcher A; Hamilton E; Coleman RL
    Cancer Treat Rev; 2023 May; 116():102546. PubMed ID: 37023499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibody-Drug Conjugates in Gynecologic Cancer.
    Karpel HC; Powell SS; Pothuri B
    Am Soc Clin Oncol Educ Book; 2023 May; 43():e390772. PubMed ID: 37229642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody-Drug Conjugates (ADC) in HER2/neu-Positive Gynecologic Tumors.
    McNamara B; Greenman M; Pebley N; Mutlu L; Santin AD
    Molecules; 2023 Nov; 28(21):. PubMed ID: 37959808
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody drug conjugates: Progress, pitfalls, and promises.
    Mukherjee A; Waters AK; Babic I; Nurmemmedov E; Glassy MC; Kesari S; Yenugonda VM
    Hum Antibodies; 2019; 27(1):53-62. PubMed ID: 30223393
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody-Drug Conjugates (ADCs) for Personalized Treatment of Solid Tumors: A Review.
    Lambert JM; Morris CQ
    Adv Ther; 2017 May; 34(5):1015-1035. PubMed ID: 28361465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibody-drug conjugates for ovarian cancer: current clinical development.
    Stewart D; Cristea M
    Curr Opin Obstet Gynecol; 2019 Feb; 31(1):18-23. PubMed ID: 30531606
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody-Drug Conjugates in Gynecologic Cancers.
    Anastasio MK; Shuey S; Davidson BA
    Curr Treat Options Oncol; 2024 Jan; 25(1):1-19. PubMed ID: 38172449
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody-drug conjugates (ADCs) for cancer therapy: Strategies, challenges, and successes.
    Abdollahpour-Alitappeh M; Lotfinia M; Gharibi T; Mardaneh J; Farhadihosseinabadi B; Larki P; Faghfourian B; Sepehr KS; Abbaszadeh-Goudarzi K; Abbaszadeh-Goudarzi G; Johari B; Zali MR; Bagheri N
    J Cell Physiol; 2019 May; 234(5):5628-5642. PubMed ID: 30478951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 52.